Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACO-REAL real-world study of acoramidis in ATTR-CM
NL-OMON58470Not yet recruiting
- Sponsor
- Bayer
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of acoramidis in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Bayer. Primary endpoint: Characteristics and treatment patterns. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
acoramidis
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON58470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58470.